Capital Group Global Equity Fund (LUX) PRegister to Unlock Ratings |
Performance History | 31/05/2024 |
Growth of 1,000 (GBP) | Advanced Graph |
Fund | - | - | -5.2 | 11.3 | 6.8 | |
+/-Cat | - | - | 4.2 | -1.4 | -0.6 | |
+/-B’mrk | - | - | 2.5 | -3.9 | -2.2 | |
Category: Global Large-Cap Blend Equity | ||||||
Category Benchmark: Morningstar Global TME NR USD |
Key Stats | ||
NAV 25/06/2024 | USD 52.42 | |
Day Change | 0.16% | |
Morningstar Category™ | Global Large-Cap Blend Equity | |
ISIN | LU2372965249 | |
Fund Size (Mil) 25/06/2024 | USD 768.39 | |
Share Class Size (Mil) 25/06/2024 | USD 8.51 | |
Max Initial Charge | 5.25% | |
Ongoing Charge 31/05/2024 | 0.75% |
Investment Objective: Capital Group Global Equity Fund (LUX) P |
Long-term capital growth through investment primarily in listed Equity, researched and selected on a world-wide basis. Unlisted securities may also be purchased, subject to the relevant provisions of the "General Investment Guidelines and Restrictions". |
Returns | |||||||||||||
|
Management | ||
Manager Name Start Date | ||
Philip Winston 22/01/2020 | ||
William Robbins 22/01/2020 | ||
Click here to see others | ||
Inception Date 16/08/2021 |
Advertisement |
Category Benchmark | |
Fund Benchmark | Morningstar Benchmark |
MSCI World NR USD | Morningstar Global TME NR USD |
Target Market | ||||||||||||||||||||
|
Portfolio Profile for Capital Group Global Equity Fund (LUX) P | 31/05/2024 |
|
|
Top 5 Holdings | Sector | % |
Novo Nordisk A/S Class B | Healthcare | 3.13 |
Broadcom Inc | Technology | 2.58 |
Microsoft Corp | Technology | 2.37 |
AstraZeneca PLC | Healthcare | 1.99 |
Safran SA | Industrials | 1.98 |
Increase Decrease New since last portfolio | ||
Capital Group Global Equity Fund (LUX) P |